Merck will invest $1 billion in a Delaware plant to manufacture Keytruda, as drugmakers ramp up U.S. production ahead of ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future drugs to market.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house U.S. site to make the blockbuster ...

Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming ...

Merck unveiled encouraging Phase 3 KEYNOTE-689 trial results for KEYTRUDA at the AACR 2025 Meeting, sparking investor ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck (MRK) is reportedly looking to expand its U.S. manufacturing presence with a $1 billion facility in Delaware, becoming the latest pharmaceutical company to boost domestic investment as ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...